NEUROCRINE BIOSCIENCES INC (NBIX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, NEUROCRINE BIOSCIENCES INC reported revenue of $2.86B, up 21.4% from the prior year. The company was profitable, with a net margin of 16.7%. It held $4.63B in total assets against $1.38B in total liabilities.
Key ratios (FY2025)
21.6%
Operating margin
16.7%
Net margin
14.7%
Return on equity
+21.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.10M | $451.20M | $161.63M | $15.00M |
| Cost of Revenue | $52.10M | $34.00M | $39.70M | $23.20M | $14.30M | $10.10M | — | $4.89M | $1.25M | $0 |
| Operating Income | $619.10M | $570.50M | $250.90M | $249.00M | $102.50M | $163.00M | $72.30M | $36.80M | -$131.36M | -$147.37M |
| Net Income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M | $407.30M | $37.00M | $21.10M | -$142.54M | -$141.09M |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993.15M | $817.59M | $365.09M |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $660.90M | $698.50M | $608.50M | $669.10M | $512.39M | $445.45M | $50.21M |
| Shareholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $636.90M | $480.80M | $372.20M | $314.88M |
| Cash & Equivalents | $713.00M | $233.00M | $251.10M | $262.90M | $340.80M | $187.10M | $112.30M | $141.71M | $254.71M | $83.27M |
| Operating Cash Flow | $782.70M | $595.40M | $389.90M | $339.40M | $256.50M | $228.50M | $147.00M | $101.40M | -$94.33M | -$106.18M |
| Capital Expenditures | $34.00M | $38.20M | $28.30M | $16.50M | $23.40M | $10.90M | $14.70M | $24.80M | $6.94M | $4.11M |
| Shares Outstanding | 102.50M | 103.70M | 101.00M | 98.90M | 97.90M | 97.80M | 95.70M | 95.40M | 88.09M | 86.71M |